https://www.live-feeds.com/feed/clues-to-why-a-breakthrough-pancreatic-cancer-drug-eventually-stops-workingContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/clues-to-why-a-breakthrough-pancreatic-cancer-drug-eventually-stops-workinghttps://www.live-feeds.com/feed/clues-to-why-a-breakthrough-pancreatic-cancer-drug-eventually-stops-working#u96585Sat, 03 Oct 2026 11:25:10 +0000Researchers are investigating why patients inevitably develop resistance to the breakthrough pancreatic cancer drug daraxonrasib. Developed by the Dana-Farber Cancer Institute and manufactured by Revolution Medicines, the medication works by blocking specific gene mutations that drive abnormal cell growth. The treatment showed so much early promise that the FDA approved it more than six months ahead of schedule. However, patients eventually stop responding to the therapy. A preliminary study recently examined biopsies from 66 patients in an early-stage trial to uncover how tumors manage to eva